Clinical trials: COPD Patients
Pulmonary Disease, Chronic Obstructive
A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients
It is hypothesised that there is a difference between the uptake of a radioactive substance ([18F]fluorodeoxyglucose (FDG)) in the lungs of patients with Chronic Obstructive Pulmonary Disease (COPD) and healthy volunteers.
- Trial name
- NCT00472264
- Testing
- PET imaging
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
COPD (Chronic Obstructive Pulmonary Disease)
Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD
This clinical trial evaluates the long-term safety and efficacy of 3 mg HSK39004 Inhalation Suspension administered twice daily for 52 weeks in subjects aged 40 to 80 years with moderate-to-severe stable chronic obstructive…
- Trial name
- NCT07634367
- Testing
- HSK39004 Inhalation Suspension
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of Indacaterol 150 µg Versus Formoterol
The study will be a 12 week treatment (84 days), parallel group, randomized, double blind, double dummy, study to assess the superiority of indacaterol (150 μg o.d.) versus formoterol (12 μg b.i.d.) in terms of trough forced…
- Trial name
- NCT01377428
- Testing
- Indacaterol, Formoterol
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.
This study is designed to assess the effect of QVA149 (110/50 ug q.d.) versus placebo on pulmonary function and average physical activity levels in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- MOVE (NCT01996319)
- Testing
- QVA149
- Where
- 30 sites in Germany
- Volunteers
- 194 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Bronchitis, Chronic Obstructive Pulmonary Disease
A Clinical Evaluation of the RheOx Bronchial Rheoplasty System
This is a prospective, multicenter, single arm and open-label clinical trial to evaluate the performance, effectiveness and safety of RheOx™ system in the treatment of the symptoms of chronic bronchitis in adult moderate to…
- Trial name
- NCT05641207
- Testing
- RheOx™ with the RheOx™ Catheter treated in the trial
- Where
- 7 sites in China
- Volunteers
- 40 people
- Sponsor
- Energenx Medical LTD.
Pulmonary Disease, Chronic Obstructive
Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
The primary objective of this study is to evaluate long-term safety and patient acceptability of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol Chlorofluorocarbon-Metered Dose Inhaler…
- Trial name
- NCT01019694
- Testing
- Combivent CFC-MDI, Combivent Respimat 20/100 mcg, Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
- Where
- 55 sites in United States
- Volunteers
- 470 people
- Sponsor
- Boehringer Ingelheim
COPD
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPD
The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.
- Trial name
- NCT00280371
- Testing
- Formoterol Fumarate
- Where
- 52 sites in United States
- Volunteers
- 345 people
- Sponsor
- Dey
Chronic Pulmonary Obstructive Disease, Emphysema
A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema
The purpose of this study is to provide post market clinical follow-up (PMCF) to obtain long term safety and efficacy information about the AeriSeal System treatment in patients with advanced emphysema.
- Trial name
- NCT01449175
- Where
- 8 sites in Austria, France and 2 more
- Volunteers
- 54 people
- Sponsor
- Aeris Therapeutics
COPD, COPD Bronchitis
NBMI - Clinical Study on COPD
A pilot study to explore safety of the treatment with the antioxidant and metal chelator NBMI in COPD patients. Investigational product: NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide), INN: Emeramide Indication: Mild, moderate…
- Trial name
- Emera003COPD (NCT03123692)
- Testing
- Emeramide
- Volunteers
- 12 people
- Sponsor
- EmeraMed
Chronic Obstructive Pulmonary Disease (COPD)
Study of Patient With Frequent COPD Exacerbations
This Study is a multicenter, non-interventional, observational, ambispective (retrospective-prospective) study to evaluate clinical and demographic characteristics, approaches to therapy in outpatients with COPD and frequent…
- Trial name
- PRIORITY-COPD (NCT07221981)
- Where
- 30 sites in Russia
- Volunteers
- 2,024 people
- Sponsor
- AstraZeneca
Smoking Cessation
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.
- Trial name
- NCT00285012
- Testing
- Varenicline Tartarate
- Where
- 32 sites in United States, France and 2 more
- Volunteers
- 504 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.
This non-Interventional, descriptive, cross-sectional cohort and multicentre study will be conducted with COPD patients attended at Spanish Primary Care offices.
- Trial name
- NCT03611777
- Testing
- Inhaled corticosteroid
- Where
- 169 sites in Spain
- Volunteers
- 901 people
- Sponsor
- Boehringer Ingelheim
Inflammatory Diseases
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.
The purpose of the study is to assess the safety and tolerability of AZD6793 suspension following oral administration of Single Ascending Dose (SAD) [Part 1] and Multiple Ascending Dose (MAD) [Part 2] in healthy participants.
- Trial name
- NCT05662033
- Testing
- AZD6793
- Where
- 2 sites in United Kingdom
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to demonstrate equivalent efficacy between two different formulations of formoterol (pMDI using HFA-134 propellant and dry powder) on lung function in adult patients with partially reversible COPD.
- Trial name
- NCT00742248
- Testing
- Formoterol
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Tiotropium and Salmeterol PK Study in COPD Patients
The primary objective of this study is to characterize the pharmacokinetics (i.e. systemic exposure to tiotropium and salmeterol) of tiotropium qd + salmeterol qd or bid versus tiotropium qd and salmeterol bid following 4-week…
- Trial name
- NCT00673478
- Testing
- Tiotropium+Salmeterol, Salmeterol, Tiotropium
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim
COPD, Cachexia
Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in COPD Cachexia
SF-K002 is a pilot study in patients with moderate to severe COPD suffering from involuntary weight loss. The study is 12 weeks, double-blinded, placebo controlled and the main objective is to study the safety and tolerability of…
- Trial name
- NCT02442908
- Testing
- Nutrifriend Cachexia
- Where
- 4 sites in Sweden
- Volunteers
- 45 people
- Sponsor
- Smartfish AS
Pulmonary Disease, Chronic Obstructive
Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To compare the long -term (six month) bronchodilator efficacy and safety of tiotropium inhalation capsules, salmeterol inhalation aerosol and placebo in patients with COPD.
- Trial name
- COPD (NCT02172287)
- Testing
- Tiotropium (Ba679 BR), Salmeterol
- Volunteers
- 623 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study was intended to assess how well inhaled NVA237 opens up the airways of patients with mild, moderate or severe COPD over a 24 hour period after a 14 day treatment period.
- Trial name
- NCT00856193
- Testing
- NVA237
- Where
- 2 sites in United States, Germany
- Volunteers
- 33 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Primary Objective: To investigate effects of SAR440340 (anti-interleukin-33 [IL-33] monoclonal antibody [mAb]) compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over up to 52…
- Trial name
- NCT03546907
- Testing
- SAR440340, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care, Any Long Acting Beta Agonist as prescribed by treating physician as standard of care
- Where
- 83 sites in United States, Argentina and 8 more
- Volunteers
- 343 people
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive
Burden of Disease Among Subjects With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)
This observational study is designed to more specifically describe the burden of the disease and the use of healthcare resources of subjects with eosinophilic COPD that may be eligible in the future for a biologic treatment.
- Trial name
- NCT03436511
- Where
- 4 sites in Spain
- Volunteers
- 341 people
- Sponsor
- GlaxoSmithKline